WO2021205289A1 - Method for transforming inhomogeneous aqueous solutions comprising inorganic and organic components into homogeneous solution - Google Patents

Method for transforming inhomogeneous aqueous solutions comprising inorganic and organic components into homogeneous solution Download PDF

Info

Publication number
WO2021205289A1
WO2021205289A1 PCT/IB2021/052679 IB2021052679W WO2021205289A1 WO 2021205289 A1 WO2021205289 A1 WO 2021205289A1 IB 2021052679 W IB2021052679 W IB 2021052679W WO 2021205289 A1 WO2021205289 A1 WO 2021205289A1
Authority
WO
WIPO (PCT)
Prior art keywords
inorganic
solution
organic
aqueous solutions
organic components
Prior art date
Application number
PCT/IB2021/052679
Other languages
French (fr)
Inventor
Ferenc Darvas
Enikő MANEK
Richard Jones
Original Assignee
InnoStudio Zrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU2100129A external-priority patent/HUP2100129A1/en
Application filed by InnoStudio Zrt. filed Critical InnoStudio Zrt.
Priority to HU2200445A priority Critical patent/HUP2200445A1/en
Publication of WO2021205289A1 publication Critical patent/WO2021205289A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus

Definitions

  • solutions used in therapy for replacing iron or other microions or the infusions which contains several inorganic and organic components in addition to the organic materials.
  • Another area of application is the case of hydroponic cultures, which are increasingly used in sustainable crop production, where 20-50, often non compatible salts, organic or inorganic plant nutrients are to be dissolved in such a way that that they neither precipitate in the so called hydroponic solution nourishing the plants nor in the devices belonging to hydroponic equipment, such as the pipelines.
  • the compatibility problems can be reduced to some extent by converting the components in the solution into nanoparticles in the usual and known manner. This can be performed by physically grinding the particles and then sieving the particles having unsuitable particle size, etc. as a physical removal. According to the common experience, the nanoparticle formation alone is not sufficient to adequately solve the non-compatibility problems (that is, to increase the solubility of one or more key components causing precipitation by at least 100-fold). It also does not lead to the solution of compatibility problems if the nanoparticles are precipitated from colloids and transfer into the mixture without preparation or optionally by filtering or by other preparation method.
  • the invention can be implemented in batch equipments, such as flasks or reactors, but it is preferred that one, more, or all of the non-incompatible salts or other compounds are nanoised in a flow reactor.
  • flow reactors include the microfluidic flow reactor described, for example, in publication: I. Homyak, B. Borcsek and F. Darvas, Microfluid Nanofluid DOI 10.1007/s 10404-008-0257-9.
  • the size of the nanoised salts according to the invention is less than 1000 nm, preferably less than 500 nm or preferably less than 300 or preferably 200 nm.
  • the salts of the invention include inorganic or organic salts in the ionic state.
  • the inorganic salts may contain, for example, the following ions: Ca 2+ , Mg 2+ , K + , NO3 , SO4 2 , H2PO4 ; the examples of ions forming organic salts include ammonium ions, e.g. NH + .
  • cellulose or derivatives thereof polysaccharides, such as mannitol or sorbitol, polyvinylpyrrolidone, sodium lauryl sulfate, gelatin, cetostearyl alcohol, polyethylene glycols, acetic acid, polyvinylpyrrolidone-vinyl acetate copolymers, sodium dodecyl benzene sulfonate, sodium dodecyl benzoyl sulfonate, tocopheryl polyethylene glycol succinate, urea, citric acid, sodium acetate, poly(oxyethylene stearate), polyvinyl alcohol (PVA), poly(methacrylate) based polymers and copolymers, 4-(l, 1,3,3- tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde groups (e.g.
  • polysaccharides such as mannitol or sorbitol
  • polyvinylpyrrolidone sodium lauryl
  • poloxamers e.g. Pluronic, which are block copolymers of propylene oxide and ethylene oxide
  • poloxamines e.g. Tetronic, which is a tetrafunctional block copolymer
  • Tetronic which is a tetrafunctional block copolymer
  • polyethylene glycol-polycaprolactam-polyvinyl acetate graft copolymers Soluplus
  • D-alpha-tocopheryl polyethylene glycol succinate poly(2-ethyl-2-oxazoline)
  • poly(methyl vinyl ether) random copolymers of vinyl pyrrolidone and vinyl acetate, such as Plasdone S630.
  • ionic stabilizers include, but are not limited to polymers, biopolymers, polysaccharides, celluloses, alginates, phospholipids, and other nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethyl methacrylate, trimethyl ammonium bromide (PMMTMABr), hexyldesyl trimethyl ammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethyl aminoethyl methacrylate dimethyl sulfate.
  • zwitterionic stabilizers poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene,
  • composition and particle size of the produced nanoparticles formed from inorganic nutrient salts measured immediately and 24 hours after redispersion.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

In many areas of life, it is necessary to prepare a homogeneous mixture from inorganic and organic salts which, under certain conditions, precipitate each other due to chemical reactions or other transformations, and thus it is impossible to prepare an aqueous solution having suitable ion composition in homogeneous form. The precipitation changes the composition of the solution and thus reduces its therapeutic or other usability. The compatibility problems can be reduced to some extent by converting the components in the solution into nanoparticles in the usual and known manner, however, according to the common experience, the nanoparticle formation alone is not sufficient to adequately solve the non-compatibility problems. The present invention provides a method for producing homogeneous solutions starting from organic and/or inorganic salts, which are non- compatible with each other.

Description

Method for transforming inhomogeneous aqueous solutions comprising inorganic and organic components into a homogeneous solution
Description
In many areas of life, it is necessary to prepare a homogeneous mixture from inorganic and organic salts which, under certain conditions, precipitate each other due to chemical reactions or other transformations, and thus it is impossible to prepare an aqueous solution having suitable ion composition in homogeneous form. This is the case, for example, with many therapeutic solutions that also contain metal ions, where the non-compatible ions often precipitate each other and a homogeneous solution cannot be prepared from them with the usual stabilizers (ionic or non-ionic additives, detergents, etc.). The precipitation changes the composition of the solution and thus reduces its therapeutic or other usability.
Examples of such solutions are the solutions used in therapy for replacing iron or other microions or the infusions, which contains several inorganic and organic components in addition to the organic materials. Another area of application is the case of hydroponic cultures, which are increasingly used in sustainable crop production, where 20-50, often non compatible salts, organic or inorganic plant nutrients are to be dissolved in such a way that that they neither precipitate in the so called hydroponic solution nourishing the plants nor in the devices belonging to hydroponic equipment, such as the pipelines.
The compatibility problems can be reduced to some extent by converting the components in the solution into nanoparticles in the usual and known manner. This can be performed by physically grinding the particles and then sieving the particles having unsuitable particle size, etc. as a physical removal. According to the common experience, the nanoparticle formation alone is not sufficient to adequately solve the non-compatibility problems (that is, to increase the solubility of one or more key components causing precipitation by at least 100-fold). It also does not lead to the solution of compatibility problems if the nanoparticles are precipitated from colloids and transfer into the mixture without preparation or optionally by filtering or by other preparation method.
In our experiments we have surprisingly found that by nanoising and then properly stabilizing the inorganic and organic components in the solution, the adequate compatibility of the solutes can be provided. The invention can be implemented in batch equipments, such as flasks or reactors, but it is preferred that one, more, or all of the non-incompatible salts or other compounds are nanoised in a flow reactor.
Examples of flow reactors include the microfluidic flow reactor described, for example, in publication: I. Homyak, B. Borcsek and F. Darvas, Microfluid Nanofluid DOI 10.1007/s 10404-008-0257-9.
The size of the nanoised salts according to the invention is less than 1000 nm, preferably less than 500 nm or preferably less than 300 or preferably 200 nm.
The salts of the invention include inorganic or organic salts in the ionic state. The inorganic salts may contain, for example, the following ions: Ca2+, Mg2+, K+, NO3 , SO42 , H2PO4 ; the examples of ions forming organic salts include ammonium ions, e.g. NH +.
For the preparation of nanoised salts of the invention the following stabilizers mentioned as representative examples can be used: cellulose or derivatives thereof, polysaccharides, such as mannitol or sorbitol, polyvinylpyrrolidone, sodium lauryl sulfate, gelatin, cetostearyl alcohol, polyethylene glycols, acetic acid, polyvinylpyrrolidone-vinyl acetate copolymers, sodium dodecyl benzene sulfonate, sodium dodecyl benzoyl sulfonate, tocopheryl polyethylene glycol succinate, urea, citric acid, sodium acetate, poly(oxyethylene stearate), polyvinyl alcohol (PVA), poly(methacrylate) based polymers and copolymers, 4-(l, 1,3,3- tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde groups (e.g. tyloxapol, superione and triton), poloxamers (e.g. Pluronic, which are block copolymers of propylene oxide and ethylene oxide), poloxamines (e.g. Tetronic, which is a tetrafunctional block copolymer), polyethylene glycol-polycaprolactam-polyvinyl acetate graft copolymers (Soluplus), D-alpha-tocopheryl polyethylene glycol succinate, poly(2-ethyl-2-oxazoline), poly(methyl vinyl ether), random copolymers of vinyl pyrrolidone and vinyl acetate, such as Plasdone S630.
Examples of useful ionic stabilizers include, but are not limited to polymers, biopolymers, polysaccharides, celluloses, alginates, phospholipids, and other nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethyl methacrylate, trimethyl ammonium bromide (PMMTMABr), hexyldesyl trimethyl ammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethyl aminoethyl methacrylate dimethyl sulfate. For support of the process of the present invention, an experiment was performed by selecting two non-compatible salts, such as calcium chloride and silver nitrate, and these were mixed into a nutrient solution used in hydroponic cultures. The experiment is shown in Figure 1. Mixing the silver nitrate with the solution containing the non-nanoised ions an abundant white precipitate formed immediately, however, if this experiment was executed with the nanoised components, we have surprisingly found that no precipitate formed, moreover, the solution remained homogeneous after 24 and 72 hours.
1. Composition and particle size of the produced nanoparticles formed from inorganic nutrient salts, measured immediately and 24 hours after redispersion.
Figure imgf000005_0001

Claims

Claims
1. Method for homogenizing inhomogeneous aqueous solutions containing inorganic and/or organic components non-compatible with each other, characterized in that one or the other or all of the compounds non-compatible with each other are nanoised in the presence of one or more organic polymers, then the nanoised components are mixed with each other.
2. Implementation of claim 1, characterized in that a flow reactor is applied to perform nanoisation.
3. Implementation of the method according to the invention, characterized in that inhomogeneity caused by gravity change in the solution is eliminated.
4. Implementation of the method according to claim 3, characterized in that a hydroponic solution, which is homogeneous even under extraterrestrial conditions, is prepared.
PCT/IB2021/052679 2020-04-06 2021-03-31 Method for transforming inhomogeneous aqueous solutions comprising inorganic and organic components into homogeneous solution WO2021205289A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HU2200445A HUP2200445A1 (en) 2020-04-06 2021-03-31 Method for transforming inhomogeneous aqueous solutions comprising inorganic and organic components into homogeneous solution

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063005529P 2020-04-06 2020-04-06
US63/005,529 2020-04-06
HU2100129A HUP2100129A1 (en) 2021-03-26 2021-03-26 Process for converting inhomogeneous aqueous solutions containing incompatible inorganic and organic components intr a homogeneous solution
HUP2100129 2021-03-26

Publications (1)

Publication Number Publication Date
WO2021205289A1 true WO2021205289A1 (en) 2021-10-14

Family

ID=89993329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/052679 WO2021205289A1 (en) 2020-04-06 2021-03-31 Method for transforming inhomogeneous aqueous solutions comprising inorganic and organic components into homogeneous solution

Country Status (2)

Country Link
HU (1) HUP2200445A1 (en)
WO (1) WO2021205289A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133418A1 (en) * 2008-04-28 2009-11-05 Nangenex Nanotechnology Incorporated Instrument and process for nanoparticles production in continuous flow mode

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133418A1 (en) * 2008-04-28 2009-11-05 Nangenex Nanotechnology Incorporated Instrument and process for nanoparticles production in continuous flow mode

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAMBERGER ANIKA, ZIENER ULRICH, LANDFESTER KATHARINA: "Encapsulation of In Situ Nanoprecipitated Inorganic Materials in Confined Geometries Into a Polymer Shell Using Inverse Miniemulsion", MACROMOLECULAR CHEMISTRY AND PHYSICS, WILEY-VCH VERLAG, WEINHEIM., DE, vol. 214, no. 6, 25 March 2013 (2013-03-25), DE , pages 691 - 699, XP055864456, ISSN: 1022-1352, DOI: 10.1002/macp.201200471 *
M N SINGH, HEMANT K, RAM M, SHIVAKUMAR H G: "Microencapsulation: A promising technique for controlled drug delivery", RESEARCH IN PHARMACEUTICAL SCIENCES, vol. 5, no. 2, 1 October 2010 (2010-10-01), pages 65 - 77, XP055502714 *
MILANI PRISCILA, FRANÇA DÉBORA, BALIEIRO ALINE GAMBARO, FAEZ ROSELENA: "Polymers and its applications in agriculture", POLIMEROS: CIENCIA Y TECNOLOGIA, ASSOCIACAO BRASILEIRA DE POLIMEROS,, BR, vol. 27, no. 3, 1 July 2017 (2017-07-01), BR , pages 256 - 266, XP055864462, ISSN: 0104-1428, DOI: 10.1590/0104-1428.09316 *
TARUN ET AL.: "Patented Microencapsulation Techniques And Its Application", JOURNAL OF PHARMACY RESEARCH, vol. 4, no. 7, July 2011 (2011-07-01), pages 2097 - 2102 *

Also Published As

Publication number Publication date
HUP2200445A1 (en) 2023-01-28

Similar Documents

Publication Publication Date Title
Hecq et al. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine
DE60210794T2 (en) ROTOR-STATOR APPARATUS AND METHOD FOR FORMING PARTICLES
EP2103364B1 (en) Process for manufacture of nanometric, monodisperse and stable metallic silver and product obtained therefrom
CN105770987B (en) A kind of 3D printing slurry of bone repairing support, bone repairing support and its preparation method and application
CN102631323A (en) Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
CN103333280B (en) A kind of method based on hydrothermal treatment consists regulation and control polystyrene microsphere monodispersity
EP2944307A1 (en) Crystalline active ingredient microparticles, method for producing the same and use thereof in drugs
TWI440601B (en) Silica sols with controlled minimum particle size and preparation thereof
WO2021205289A1 (en) Method for transforming inhomogeneous aqueous solutions comprising inorganic and organic components into homogeneous solution
CN1878602A (en) Manufacturing method of organic compound particulate
KR102424025B1 (en) Method for producing organic material microparticles, and method for modifying organic material microparticles
CN112108193A (en) Microfluidic preparation method for regulating and controlling particle size of liposome
CN107412193A (en) Nano hybridization pharmaceutical carrier and its preparation method prepared by the Pickering emulsion template methods using magadiite as emulsifying agent
CN110016150B (en) Method for stabilizing Pickering inverse miniemulsion through macromolecular self-assembly
CN1104137A (en) Super-fine globular silver-palladium alloy powder production method
KR101378470B1 (en) Method of synthesizing metal composite oxide and metal composite oxide obtained by same
CN103691373A (en) Method for preparing nano capsule
CN117084984A (en) Method for efficiently preparing dimetanidazole premix
CN102356094A (en) Process for purifying guar
CN105616369A (en) Preparation method of dissolution-enhanced fenofibrate chip
JP7103608B2 (en) Manufacturing method of recycled material using unused ready-mixed concrete
EP2925791B1 (en) Manufacturing processes for gellan gum-based fluid gels
CN113521001A (en) Preparation method of suspension containing dexamethasone
Khan et al. Enhanced dissolution rate of Ketoprofen by fabricating into smart nanocrystals.
WO2012117562A1 (en) Method for manufacturing nanoparticle dispersion liquid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21785697

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21785697

Country of ref document: EP

Kind code of ref document: A1